MCC-950

NLRP3 (MCC950) was originally found to act as a cytokine release inhibitory drug (CRID), arresting activated monocytes and preventing activation of caspase-1(1). Discovered to be a novel inhibitor of the NLRP3 and AIM2 inflammasomes(2). Blocks canonical and noncanonical NLRP3 activation at nanomolar concentrations3. Inhibits interleukin 1β (IL-1β) secretion in vivo and attenuates the severity of experimental autoimmune encephalomyelitis (an MS disease model)(3). Disrupts the interaction between AIM2 and ASC in a reconstituted cell-free inflammasome(4). A valuable new tool for exploring the pathophysiology of NLRP3. It may contribute to additional alpha synuclein aggregation and cell loss in PD (5).

1. Laliberte R.E. et al. (2003) J. Biol. Chem. 278(19):16567-78. 2. Coll R.C., et al. (2011) PLoS One. 6(12):e29539. 3. Coll R.C., et al. (2015) Nat. Med. 21(3):248-255. 4. Kaneko N., et al. (2015) J. Immunol. Methods. 426:76-81. 5. Nguyen L., et al. (2022) J Parkinsons Dis. 12(7): 2117-2133.